ARTICLE | Clinical News
Procept begins Phase II
February 11, 2000 8:00 AM UTC
Procept ( Cambridge, Mass.), a subsidiary of HeavenlyDoor.com (HVDC), began a U.S. Phase II trial of its 0-6-Benzylguanine chemosensitizing agent in combination with carmustine to treat cerebral anapl...